viewCanntab Therapeutics Ltd

Canntab Therapeutics teams up with World Class Extractions to process and manufacture CBD pills

The two companies are establishing a joint venture that will see World Class Extractions install its cannabis extraction and processing systems for Canntab to manufacture medical cannabis in pill form

Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract

Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) announced Tuesday that it is teaming up with World Class Extractions (CSE:PUMP) to process cannabis derivatives from its Markham, Ontario facility. 

The two companies are establishing a joint venture that will see World Class Extractions (WCE) install its cannabis extraction and processing systems for Canntab to manufacture medical cannabis in pill form.

Shares of Canntab soared on Tuesday morning, up 24% at C$0.57 in Canada.

READ: Canntab's plans boosted by initial indication of patentability for its immediate release CBD formulation

Toronto-based Canntab will start production once it receives its license from Health Canada, which is expected shortly.

WCE’s systems include turnkey components from its portfolio of machines, such as the BOSS next-generation CO2 cannabis extraction system.

Canntab CEO Jeff Renwick told investors in a Tuesday statement that the agreement is driven in part by the constrained supply and unsustainable pricing within the extraction marketplace.

"Having the BOSS and World-Class' expertise will give Canntab the ability to control its own destiny by securing an ongoing supply for its manufacturing operations, where required,” Renwick said.

Multiple separation technologies including chromatography will also allow Canntab to separate the various cannabinoids and terpenoids, in order to diversify and expand its portfolio of cannabis-based solid oral dosage forms, according to Renwick.

“With these elements, such as CBN and CBG, Canntab will be able to do further research into promising formulations that may approach a range of medical conditions.”

Processing capacity

Under the terms of the agreement, Canntab and WCE will each hold 50% interest in the joint venture. The equipment will have an initial extraction and processing capacity of up to 225 kilograms of biomass per day, which could result in around 18 kilograms of CBD oil. The oil could then be used to create about 1.8 million 10mg tablets.

The extraction and processing systems will remain the property of WCE until all costs are recovered, at which point the equipment will become the property of the joint venture.

WCE CEO Rosy Mondin said that the extraction company looks forward to supporting Canntab's growth as a global leader of research and production of hard-pill oral dosage therapeutic cannabis product forms.

“Our WCE team has spent the last half-decade concentrating on R&D to bring leading technology and solutions to cannabis and hemp oil extraction,” Mondin said in a statement.

Canntab will continue to contract with third-party suppliers such as Heritage Cannabis Corp (CSE:CANN) - an agreement was signed in May 2019. The systems received from WCE will augment Canntab’s own capacity.

--Updated with share price--

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Canntab Therapeutics Ltd

Price: 0.63 CAD

Market: CSE
Market Cap: $19.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...



Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

on 06/02/2020

3 min read